About cnetsadmin

This author has not yet filled in any details.
So far cnetsadmin has created 69 blog entries.

Board Recruitment Announcement

Are you looking for a unique leadership opportunity? Have you been yearning to put your talent in strategic thinking, financial analysis, project management, communications or policy advocacy in the [...]

By |2023-05-21T16:04:10-04:00May 21st, 2023|Uncategorized|Comments Off on Board Recruitment Announcement

Somatuline Motorized Delivery Device – Press Release

Ipsen announces investment in new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) designed to improve patient experience. New electronic autoinjector is designed to improve patient experience for [...]

By |2023-04-09T15:37:34-04:00April 9th, 2023|Treatment News|Comments Off on Somatuline Motorized Delivery Device – Press Release

CNETS Board Member Awareness

CNETS Board Member Awareness Patient Education and Fundraising A core function of CNETS is to offer the Canadian neuroendocrine cancer community useful, [...]

By |2021-11-05T04:34:17-04:00November 4th, 2021|Awareness|Comments Off on CNETS Board Member Awareness

Pewter Zebra Keyfobs/Pendants

Volunteers create one-of-a-kind handmade Pewter Zebra Keyfobs/Pendants to help raise awareness & funds for CNETS Al Gillis is a neuroendocrine cancer patient and member of the Toronto Patient and [...]

By |2021-09-11T09:23:41-04:00August 23rd, 2021|Awareness, News|Comments Off on Pewter Zebra Keyfobs/Pendants

Temozolomide Access in Ontario

CNETS is pleased to share the news that the oral chemotherapy drug, temozolomide, often used in combination with capecitabine, known as the CAPTEM regimen, is now more accessible to [...]

By |2021-07-07T21:48:16-04:00July 6th, 2021|Treatment News|Comments Off on Temozolomide Access in Ontario

Lutathera Funded in Saskatchewan

As of June 1, 2021, Lutathera is now available in Saskatchewan. The reimbursement criteria is for patients with unresectable, well-differentiated midgut* neuroendocrine tumors (NET) in patients who have experienced [...]

By |2021-07-06T18:30:28-04:00July 6th, 2021|Treatment News|Comments Off on Lutathera Funded in Saskatchewan
Go to Top